Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review

Bridge, Simon; BASSENDINE, Margaret F.

doi:10.5152/eurjrheum.2019.19152

Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review

Margaret F. BASSENDINE, (Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK / Department of Hepatology & Gastroenterology, Imperial College London, London, UK)

Simon H. BRIDGE (Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK / Northumbria University, School of Health and Life Sciences, Newcastle upon Tyne, UK)

European Journal of Rheumatology

7 0

Yıl: 2020 Cilt: 7 Sayı: 1 Sayfa Aralığı: 37 - 40 Metin Dili: İngilizce DOI: 10.5152/eurjrheum.2019.19152 İndeks Tarihi: 13-05-2021

Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review

Öz:

Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatological condition affecting individuals aged >50 years. There have been rare reports of PMR and other vasculitides developing within 3 months of influenza vaccination. Influenza is a major public health issue associated with seasonal increased mortality and intensified health care service use. Annual vaccination is the most effective intervention to prevent influenza, especially in elderly individuals. We report a severe "flare" of PMR in a 70-year-old patient after receiving the adjuvanted trivalent influenza vaccine, as recommended by the Joint Committee on Vaccination and Immunisations for this age group in the UK National Health Service in 2018-2019. The adverse event (AE) could be interpreted as the newly described autoimmune/inflammatory syndrome induced by adjuvants (ASIA syndrome) as both PMR and ASIA display hyperactive immune responses. Caution is warranted in the use of vaccine adjuvants in patients with PMR with pre-existing imbalance of B and T cell homeostasis. Rare AEs are important to individuals, and personalized medicine means we should move away from "one size fits all" for vaccines, as well as for therapeutics.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık

1. Gonzalez-Gay MA, Matteson EL, Castaneda S. Polymyalgia rheumatica. Lancet 2017; 390: 1700-12. [CrossRef]
2. van der Geest KS, Abdulahad WH, Chalan P, Rutgers A, Horst G, Huitema MG, et al. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica. Arthritis Rheumatol 2014; 66: 1927-38. [CrossRef]
3. Felicetti P, Trotta F, Bonetto C, Santuccio C, Brauchli Pernus Y, Burgner D, et al. Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. Vaccine 2016; 34: 6634-40. [CrossRef]
4. Soriano A, Verrecchia E, Marinaro A, Giovinale M, Fonnesu C, Landolfi R, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus 2012; 21: 153-7. [CrossRef]
5. Iwata K, Mizuno Y. A case of polymyalgia rheumatica following influenza B infection. Int J Gen Med 2015; 8: 345-7. [CrossRef]
6. Vestergaard LS, Nielsen J, Krause TG, Espenhain L, Tersago K, Bustos Sierra N, et al. Excess allcause and influenza-attributable mortality in Europe, December 2016 to February 2017. Euro Surveill 2017; 22: 30506. [CrossRef]
7. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 2018; 378: 345-53. [CrossRef]
8. Pebody RG, Warburton F, Andrews N, Sinnathamby M, Yonova I, Reynolds A, et al. Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17. Euro Surveill 2018; 23. [CrossRef]
9. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371: 635-45. [CrossRef]
10. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19: 1597- 608. [CrossRef]
11. Domnich A, Arata L, Amicizia D, Puig-Barbera J, Gasparini R, Panatto D. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine 2017; 35: 513-20. [CrossRef]
12. Liu X, Tharmarajah K, Taylor A. Ross River virus disease clinical presentation, pathogenesis and current therapeutic strategies. Microbes Infect 2017; 19: 496-504. [CrossRef]
13. Bitik B, Mercan R, Tufan A, Tezcan E, Kucuk H, Ilhan M, et al. Differential diagnosis of elevated erythrocyte sedimentation rate and C-reactive protein levels: a rheumatology perspective. Eur J Rheumatol 2015; 2: 131-4. [CrossRef]
14. Devey ME, Bleasdale-Barr KM, Bird P, Amlot PL. Antibodies of different human IgG subclasses show distinct patterns of affinity maturation after immunization with keyhole limpet haemocyanin. Immunology 1990; 70: 168-74.
15. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6: 699-710. [CrossRef]
16. Phillips CJ, Matyas GR, Hansen CJ, Alving CR, Smith TC, Ryan MA. Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. Vaccine 2009; 27: 3921-6. [CrossRef]
17. Carlson BC, Jansson AM, Larsson A, Bucht A, Lorentzen JC. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000; 156: 2057-65. [CrossRef]
18. Holm BC, Lorentzen JC, Bucht A. Adjuvant oil induces waves of arthritogenic lymph node cells prior to arthritis onset. Clin Exp Immunol 2004; 137: 59-64. [CrossRef]
19. Shoenfeld Y, Agmon-Levin N. 'ASIA' - autoimmune/ inflammatory syndrome induced by adjuvants. J Autoimmun 2011; 36: 4-8. [CrossRef]
20. Cruz-Tapias P, Agmon-Levin N, Israeli E, Anaya JM, Shoenfeld Y. Autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA)--animal models as a proof of concept. Curr Med Chem 2013; 20: 4030-6. [CrossRef]
21. Watad A, Quaresma M, Bragazzi NL, Cervera R, Tervaert JWC, Amital H, et al. The autoimmune/ inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry. Clin Rheumatol 2018; 37: 483-93. [CrossRef]
22. Watad A, Bragazzi NL, McGonagle D, Adawi M, Bridgewood C, Damiani G, et al. Autoimmune/ inflammatory syndrome induced by adjuvants (ASIA) demonstrates distinct autoimmune and autoinflammatory disease associations according to the adjuvant subtype: Insights from an analysis of 500 cases. Clin Immunol 2019; 203: 1-8. [CrossRef]
23. Brauner S, Folkersen L, Kvarnstrom M, Meisgen S, Petersen S, Franzen-Malmros M, et al. H1N1 vaccination in Sjogren's syndrome triggers polyclonal B cell activation and promotes autoantibody production. Ann Rheum Dis 2017; 76: 1755-63. [CrossRef]
24. Schmits R, Kubuschok B, Schuster S, Preuss KD, Pfreundschuh M. Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica. Clin Exp Immunol 2002; 127: 379-85. [CrossRef]
25. Baerlecken NT, Linnemann A, Gross WL, Moosig F, Vazquez-Rodriguez TR, Gonzalez-Gay MA, et al. Association of ferritin autoantibodies with giant cell arteritis/polymyalgia rheumatica. Ann Rheum Dis 2012; 71: 943-7. [CrossRef]
26. Lofano G, Mancini F, Salvatore G, Cantisani R, Monaci E, Carrisi C, et al. Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination. J Immunol 2015; 195: 1617-27. [CrossRef]
27. Samson M, Audia S, Fraszczak J, Trad M, Ornetti P, Lakomy D, et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 2012; 64: 3788-98. [CrossRef]
28. Edwards K, Hanquet G, Black S, Mignot E, Jankosky C, Shimabukuro T, et al. Meeting report narcolepsy and pandemic influenza vaccination: What we know and what we need to know before the next pandemic? A report from the 2nd IABS meeting. Biologicals 2019; 60: 1-7. [CrossRef]
29. Chandler RE. Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events. BMJ 2019; 365: l2268. [CrossRef]
30. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013; 19: 1305- 12. [CrossRef]

APA	BASSENDINE M, Bridge S (2020). Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. , 37 - 40. 10.5152/eurjrheum.2019.19152
Chicago	BASSENDINE Margaret F.,Bridge Simon Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. (2020): 37 - 40. 10.5152/eurjrheum.2019.19152
MLA	BASSENDINE Margaret F.,Bridge Simon Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. , 2020, ss.37 - 40. 10.5152/eurjrheum.2019.19152
AMA	BASSENDINE M,Bridge S Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. . 2020; 37 - 40. 10.5152/eurjrheum.2019.19152
Vancouver	BASSENDINE M,Bridge S Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. . 2020; 37 - 40. 10.5152/eurjrheum.2019.19152
IEEE	BASSENDINE M,Bridge S "Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review." , ss.37 - 40, 2020. 10.5152/eurjrheum.2019.19152
ISNAD	BASSENDINE, Margaret F. - Bridge, Simon. "Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review". (2020), 37-40. https://doi.org/10.5152/eurjrheum.2019.19152

APA	BASSENDINE M, Bridge S (2020). Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. European Journal of Rheumatology, 7(1), 37 - 40. 10.5152/eurjrheum.2019.19152
Chicago	BASSENDINE Margaret F.,Bridge Simon Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. European Journal of Rheumatology 7, no.1 (2020): 37 - 40. 10.5152/eurjrheum.2019.19152
MLA	BASSENDINE Margaret F.,Bridge Simon Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. European Journal of Rheumatology, vol.7, no.1, 2020, ss.37 - 40. 10.5152/eurjrheum.2019.19152
AMA	BASSENDINE M,Bridge S Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. European Journal of Rheumatology. 2020; 7(1): 37 - 40. 10.5152/eurjrheum.2019.19152
Vancouver	BASSENDINE M,Bridge S Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review. European Journal of Rheumatology. 2020; 7(1): 37 - 40. 10.5152/eurjrheum.2019.19152
IEEE	BASSENDINE M,Bridge S "Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review." European Journal of Rheumatology, 7, ss.37 - 40, 2020. 10.5152/eurjrheum.2019.19152
ISNAD	BASSENDINE, Margaret F. - Bridge, Simon. "Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review". European Journal of Rheumatology 7/1 (2020), 37-40. https://doi.org/10.5152/eurjrheum.2019.19152